Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.
Actively Recruiting
Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.
Actively Recruiting
Researchers are evaluating the Allay4 Aortic Stent as an additional endovascular treatment for patients with Type B aortic dissection who are eligible for thoracic endovascular aortic repair TEVAR using stent grafts. The study focuses on patients who have already been selected for proximal TEVAR based on standard care. It aims to determine if the Allay4 Aortic Stent reduces the risk of aortic growth needing further treatment or rupture in the treated abdominal aorta within 12 months, while also assessing safety events within 30 days post-implantation. Participants will first receive a covered thoracic stent graft in the supraceliac position as part of standard treatment. Then, the investigational Allay4 Aortic Stent will be implanted inside the stent graft, extending below the celiac trunk to the end of the dissected aorta, typically down to the aortoiliac bifurcation. This procedure is done after the initial TEVAR and follows local guidelines for patient selection and device use. During the study, participants will undergo clinical and imaging assessments including CT scans to monitor aortic dimensions, device performance, and presence of complications. Researchers will track major adverse events within the first 30 days and evaluate freedom from aortic growth requiring reintervention or rupture at 12 months. Follow-up will continue up to 60 months to assess long-term outcomes such as mortality, reinterventions, and device-related issues, with regular visits and imaging studies scheduled throughout this time.
Actively Recruiting
Researchers are conducting an international multicenter prospective cohort study to collect data on breast reconstruction techniques using pre-pectoral implants after mastectomy for breast cancer. The study aims to gather information on surgical, aesthetic, and cancer-related outcomes, as well as patient quality of life following this specific type of breast reconstruction. The study involves 1,236 female patients who undergo mastectomy and subsequent pre-pectoral implant-based breast reconstruction using an implant or expander, with or without mesh. Being an observational study, patients diagnostic and treatment plans will not be altered, and no additional risks are expected. The study will evaluate outcomes such as implant loss, infections, re-admissions, re-operations, and complications at several time points postoperatively. Participants will be monitored up to 24 months after surgery to assess quality of life and track early and late complications related to the reconstruction. Data collection will occur at intervals including three months, six months, 12 months, and 24 months post-surgery. This study helps provide future patients and surgeons with valuable information to guide decisions about breast reconstruction using the pre-pectoral approach.
Actively Recruiting
Researchers are collecting detailed imaging and clinical data from patients with atrial fibrillation or atrial flutter who undergo transesophageal echocardiography to better understand and predict the risks associated with left atrial appendage thrombus LAT. This observational study aims to develop artificial intelligence models that analyze transthoracic echocardiography images and clinical information to predict the presence of LAT, which is linked to stroke risk and complicates cardioversion or catheter ablation procedures. The study involves gathering multimodal imaging data including transesophageal echocardiography, transthoracic echocardiography, cardiac CT, cardiac magnetic resonance, and electrocardiograms, both retrospectively and prospectively. Patients undergo clinically indicated transesophageal echocardiography before catheter ablation or cardioversion. Optional imaging modalities and clinical data are collected to form a comprehensive database that supports AI-based model development and validation. Participants will have their imaging data and clinical records collected during hospitalization, with follow-up data on adverse outcomes and atrial fibrillation recurrence tracked for up to one year. Researchers will assess the presence of left atrial appendage thrombus using these data, aiming to improve diagnostic and therapeutic approaches. The study involves no treatment administration but focuses on detailed imaging acquisition and clinical monitoring to support artificial intelligence research.
Actively Recruiting
Researchers are collecting and analyzing real-world data from multiple centers in Italy and Poland on the use of the PERCUTEK Tycheseal stent-graft system for repairing abdominal aortic aneurysms AAA. The study aims to evaluate the technical success, safety, and mid-term outcomes of this device in actual clinical practice. It focuses on patients with suitable anatomy undergoing this procedure, to provide evidence on the devices performance and related complications over time. This is an observational, physician-initiated registry enrolling 120 to 200 patients over about 18 months. Participants receive the PERCUTEK Tycheseal tri-modular endograft system, which includes a main body and two iliac limbs designed to fit a range of aortic anatomies. The device features a low-profile delivery system and radiopaque markers to aid placement. Data on the procedure and outcomes are collected without experimental treatments or randomization. Participants are followed for up to 24 months after device implantation with assessments at baseline, discharge, 1 month, 12 months, and 24 months. Study measures include technical success defined by proper device positioning and no immediate serious leaks, aneurysm size changes, endoleak presence, device migration or occlusion, and major adverse events. Data are collected using standardized forms, and safety outcomes are monitored throughout the study period to understand the devices mid-term clinical performance.
Actively Recruiting
Researchers are studying the combination of RVU120 and venetoclax in adults with acute myeloid leukemia AML that has returned or not responded to prior treatment with venetoclax and a hypomethylating agent. This Phase 2 trial aims to determine safe and tolerated doses, assess the treatments safety and effectiveness, and confirm these findings in a larger group of patients. Participants receive oral doses of RVU120 every other day and venetoclax daily in 21-day cycles. The study has three parts Part 1 involves dose escalation to find safe doses Part 2 evaluates safety and response at these doses and Part 3 confirms efficacy and safety in more patients using the recommended doses from Part 2. During the study, participants are monitored for safety, treatment response, and drug behavior in the body through regular assessments. Researchers track remission rates, side effects, blood transfusion needs, survival outcomes, and the impact on patient-reported quality of life. The study lasts approximately 36 months with ongoing evaluations throughout the treatment cycles.
Actively Recruiting
Researchers are evaluating fazirsiran, an investigational drug, to see if it can reduce liver scarring fibrosis and slow disease progression in people with liver disease caused by an abnormal alpha-1 antitrypsin protein. The study compares fazirsiran to a placebo and aims to understand how the drug affects the body, including its impact on liver inflammation and abnormal protein levels. Liver biopsies will be taken twice to assess changes in liver scarring. Participants will receive either fazirsiran or a placebo through subcutaneous injections. The dosing schedule includes an injection on Day 1, at Week 4, and then every 12 weeks up to Week 196. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. During the study, participants will undergo liver biopsies and various assessments including imaging techniques and blood tests to monitor liver function, protein levels, liver stiffness, and inflammation. Researchers will also track side effects, lung function, vital signs, and laboratory results from the start of treatment through up to Week 230. The main focus is on measuring changes in liver fibrosis after 106 weeks, with ongoing safety and efficacy evaluations throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of DM199 rinvecalinase alfa in adults who have experienced an acute ischemic stroke due to small and medium vessel blockages. This Phase 23 randomized, double-blind, placebo-controlled study focuses on patients with moderate stroke severity who present within 24 hours of stroke onset and have limited treatment options. Participants undergoing mechanical thrombectomy or those who received fibrinolytics without persistent neurological symptoms after 6 hours are not eligible. The study aims to improve outcomes for this specific population. Participants will be randomly assigned to receive either DM199 or a placebo. The treatment involves a single intravenous dose followed by subcutaneous doses starting 2 hours plus or minus 10 hours after the IV dose, then twice weekly up to Day 21. The study includes an interim analysis after 200 participants complete their 90-day assessment to evaluate safety and potentially adjust the sample size, with up to 728 participants planned. Treatments are administered under careful medical supervision. During the approximately 90-day participation, individuals will undergo various assessments including evaluations of stroke recovery, disability, neurological function, mortality, functional independence, and recurrence of acute ischemic stroke, all measured at Day 90. Participants will be monitored closely through these visits and assessments to track their progress and safety throughout the study and follow-up period.